FDA grants Tecentriq sLBA priority review in non-small cell lung cancer – Genentech/Roche
Genentech/Roche announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) as adjuvant treatment following surgery and platinum-based… read more.